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Abstract Ecopharmacovigilance (EPV) is a developing
science and it is currently very unclear what it might mean
in practice. We have performed a comparison between
pharmacovigilance (PV) and EPV and have identified that
there are similarities, but also some important differences
that must be considered before any practical implementa-
tion of EPV. The biggest difference and greatest challenge
concerns signal detection in the environment and the dif-
ficulty of identifying cause and effect. We reflect on the
dramatic vulture decline in Asia, which was caused by the
veterinary use of diclofenac, versus the relative difficulty in
identifying the specific causes of intersex fish in European
rivers. We explore what EPV might mean in practice and
have identified that there are some practical measures that
can be taken to assess environmental risks across product
life cycle, particularly after launch of a new drug, to ensure
that our risk assessments and scientific understanding of
pharmaceuticals in the environment remain scientifically
and ecologically relevant. These include:
• Tracking environmental risks after launch of the
product, via literature monitoring for emerging data
on exposure and effects
• Using Environmental Risk Management Plans
(ERMPs) as a centralized resource to assess and
manage the risks of a drug throughout its life cycle
• Further research, testing or monitoring in the environ-
ment when a risk is identified
• Keeping a global EPV perspective
• Increasing transparency and availability of environ-
mental data for medicinal products.
These measures will help to ensure that any significant
environmental issues associated with pharmaceuticals in
the environment (PIE) are identified in a timely way, and
can be managed appropriately.
1 Introduction
In recent years concern has been expressed over the
potential impact of pharmaceuticals in the environment
(PIE) and consequently a comprehensive Environmental
Risk Assessment (ERA) is now a regulatory requirement
prior to launch of any new drug. However, there is no
formal framework or mechanism to review the ERA, or to
monitor for potential adverse effects in the environment,
once a product has been launched.
Within Europe, the Pharmacovigilance Framework [1]
includes a reference to the pollution of waters and soils with
pharmaceutical residues and states that ‘‘Member states should
consider measures to monitor and evaluate the risk of envi-
ronmental effects, including those which may have an impact on
public health’’. This suggests that a kind of PV for the envi-
ronment, or ecopharmacovigilance (EPV), should be explored.
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The aim of this article is to explore what EPV might
mean in practice and to discuss some of the challenges and
potential opportunities that need to be faced when trying to
implement EPV procedures. We also describe our approach
to developing Environmental Risk Management Plans
(ERMPs), which start to address some of the challenges of
EPV.
2 What is Ecopharmacovigilance (EPV)?
Before introducing the EPV concept, some background is
necessary on PIE and the ERA of pharmaceuticals.
2.1 Pharmaceuticals in the Environment
In recent years, human pharmaceuticals from numerous
therapeutic classes have increasingly been detected in the
environment, typically at ng/L to low lg/L in surface
waters [2–17]. The potential routes of environmental entry
have been extensively reviewed. These include (i) patient
excretion either as parent compound or metabolites via the
sewer system, (ii) direct release into the waste water sys-
tem from manufacturing, hospitals or disposal via toilets/
sinks, and (iii) terrestrial depositions, for example via
sludge application to land, leaching from solid waste
landfills, or irrigation with treated or untreated wastewaters
[4, 13, 16, 18, 19].
It is generally accepted that excretion of pharmaceuti-
cals after human and veterinary therapeutic use dominates
the global input of pharmaceuticals into the environment.
Manufacturing effluent discharges and the disposal of
unused drugs make a relatively small contribution to the
overall environmental load [8, 16, 20, 21]. Nevertheless,
localized elevated drug concentrations can occur adjacent
to discharges from hospitals [22] and manufacturing sites if
emissions are not properly treated and controlled [23–25].
Proactive initiatives to manage pharmaceutical manufac-
turing and formulation wastes have been described else-
where [26, 27]. Similarly, disposal of unused drugs is a
very specific issue that can be managed effectively if the
appropriate preventative methods are put in place. This
may include guidance for patients, take-back schemes and
disposal practices [21]. Pharmaceutical residues in the
environment associated with human excretion are an
inevitable consequence of patient drug use, and unlike
manufacturing-related releases and unused drugs, it is a
much more difficult source to control. The level of effec-
tive sewage treatment in a particular region may reduce the
resulting concentrations, but there will still be some resi-
dues remaining, so the question remains as to whether or
not such residues present any significant risk, and what
level of residues is acceptable. This question is routinely
addressed for new drugs by undertaking an ERA as part of
the regulatory approval process.
2.2 Environmental Risk Assessment
of Pharmaceuticals
In both Europe and North America, there are regulatory
requirements governing the ERA of human pharmaceuti-
cals [28, 29]. It is widely accepted that the European Union
(EU) regulations are currently the most demanding and
data intensive. In most cases, a new regulatory submission
or line extension has to be accompanied by an ERA, which
requires environmental fate and effects tests to be
undertaken.
ERA is addressed through the generation of a risk
quotient, i.e. the ratio of the predicted environmental
concentration (PEC) to the predicted no-effect concentra-
tion (PNEC) ratio (PEC:PNEC). The PEC provides an
estimate of the maximum concentration anticipated to
occur in the environment, resulting from patient use and
subsequent excretion into the wastewater system. The
PNEC is derived from ecotoxicological tests, normally on
algae, daphnids and fish (representing three trophic levels),
together with an assessment factor that accounts for inter-
species differences in toxicity. Typically, worst-case
assumptions are initially made in deriving the PEC (e.g.,
100 % excretion by patients, no removal during sewage
treatment), and generally if the PEC:PNEC is\1 no further
information is required. Conversely, if PEC:PNEC is [1
then additional testing is generally needed to refine the
PEC or PNEC. If this fails to refine the risk quotient to\1
then appropriate risk management measures may need to
be put in place.
The ERA must normally be in place prior to approval of
a new drug in the EU, and if an environmental risk is
identified, ‘‘specific arrangements to limit it should be
envisaged’’ [29]. However, there is no requirement for an
ERA to be updated or reviewed once a new drug has been
approved.
2.3 Definition of EPV
The term ‘ecopharmacovigilance’ was first coined by Velo
[30]. However, a number of other articles have proposed
terms to describe this newly emerging field: ecopharma-
cology [31], environmental pharmacology [32], pharma-
coenvironmentology [33], pharmacovigilance [21, 34] and
ecopharmacostewardship [35]. Whilst these articles intro-
duce the concept of EPV, and some approaches to EPV,
they tend to cover a much broader scope that captures all
areas of sustainable pharmacy, such as green drug design,
green chemistry in process development, minimization of
manufacturing emissions, improved prescribing practices
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and the management of unused drugs. In addition, many of
the EPV approaches that have been advocated to date have
been largely preventative in nature and have assumed that
the presence of pharmaceuticals in the environment will
inevitably result in an adverse impact without any con-
sideration of likelihood of impact or risk. As such many of
the approaches advocated under EPV are simply designed
to reduce the environmental concentrations of pharma-
ceuticals. In taking this preventative approach, EPV could
be in danger of failing to relate field-based observations to
the environmental risk assessments, or to understanding
whether pharmaceuticals actually result in adverse envi-
ronmental impacts, and, if so, how. It also fails to consider
the relative impact that pharmaceuticals have on ecosys-
tems versus other environmental stimuli.
PV has been defined by the World Health Organisation
(WHO) as ‘‘the science and activities relating to the
detection, assessment understanding and prevention of
adverse effects or any other possible drug related prob-
lems’’ [36, 37]. Thus, a reasonable starting point for EPV is
to take this definition and directly apply it to the environ-
ment. In doing so, EPV would describe the science and
activities associated with the detection, evaluation,
understanding and prevention of adverse effects of phar-
maceuticals in the environment. This definition of EPV
reflects the approach communicated at the International
Society of Pharmacovigilance annual meeting in Ghana in
November 2010 [38], and that endorsed by Velo and Mo-
retti [39].
2.4 Comparison of Pharmacovigilance (PV) with EPV
Both PV and EPV aim to monitor the adverse effects of
pharmaceuticals, PV in patients and EPV in the environ-
ment but potentially also in humans through indirect non-
therapeutic exposure. Exposure to drugs in humans is well
defined through clinical trials by knowing the dose given
and measuring plasma levels, which can in turn in some
instances be correlated to adverse drug reactions (ADRs).
Conversely, whilst drugs and their metabolites can be
detected in the environment and their concentrations
measured or predicted, apart from a limited number of
studies [40, 41], actual exposure in wildlife is generally not
known. Drugs prescribed to patients are monitored, and
ADRs identified, discussed and clarified as necessary
through the PV process. In contrast, species in the envi-
ronment are not routinely monitored (unless there is a
specific reason to do so) and there is no equivalent to the
doctor-patient interaction that is so important for identi-
fying ADRs in patients.
PV is highly regulated in most countries around the
world [29, 37] with pharmaceutical companies subject to
inspection and dissuasive disciplinary measures in cases of
non-compliance. In contrast, EPV is a new concept and an
emerging science that is not regulated.
Last, but by no means least, determining a causal rela-
tionship between a drug, or a combination of drugs, and a
possible ADR in an individual patient or a population
group is not always straightforward but it is nowhere near
as difficult as attributing adverse environmental impacts on
environmental species to a single cause such as an indi-
vidual drug, combination of drugs or a drug metabolite.
This is compounded further by the presence of other syn-
thetic and natural chemicals in the environment, and/or
other environmental factors that may or may not contribute
towards an observed adverse environmental impact. Some
of the similarities and differences between EPV and PV are
highlighted in Table 1.
2.5 Determining a Relationship between Cause
and Effect in the Environment
Unlike many other chemicals that enter the environment,
human drugs are designed to have highly specific interac-
tions with their intended biochemical target in their
intended target species [42]. It is these unique properties
that raised questions over the potential impact of pharma-
ceuticals in the environment, in terms of their potential
interaction with aquatic life, higher predators and humans
[43]. Despite the widespread detection of pharmaceuticals
in the environment and the potential for effects in wildlife
species, there is only one identified case in which an
adverse environmental impact in the field has been solely
attributed to a pharmaceutical. Diclofenac, a non-steroidal
anti-inflammatory drug, is the only well documented
example where a pharmaceutical has resulted in an adverse
population-level impact on non-target populations in the
wild [44]. This was through its veterinary application in
South-East Asia to treat inflammation and fever in
domestic livestock. Vultures ingested diclofenac when
feeding on the carcasses of livestock that had been treated
with high doses shortly before their deaths. It is estimated
that somewhere between 10 and 40 million vultures have
been poisoned, and that three species of Gyps vultures are
now critically endangered [45]. Gyps vultures are extre-
mely sensitive to diclofenac and exposure to the drug
causes abdominal gout and acute kidney failure. The lethal
dose for renal failure is of the order of 0.1–0.2 mg/kg [46,
47]. Acute effects have also been observed in the African
white-backed vulture (Gyps africanus) and the Eurasian
griffon vulture (Gyps fulvus) [48] as a result of diclofenac
exposure. However, the North American species of vulture
such as Cathartes aura appear to be less sensitive than
Gyps vultures by exposure to diclofenac [49]. Rapid pop-
ulation declines have also been observed in non-Gyps
vulture populations in South America and Asia [50], but
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the cause of these declines has not yet been established. A
key factor that facilitated the link between the population
decline in vultures with diclofenac exposure was the scale
of the population decline and the acute impact the dic-
lofenac had. However, it is extremely unlikely that any
other human pharmaceuticals will cause such obvious
acute effects on wildlife and, consequently, it may prove
extremely challenging to link chronic adverse impacts on
wildlife with a specific pharmaceutical or group of phar-
maceuticals with the same mechanism of action [45].
A classic example is the case of ethinylestradiol (EE2), a
known potent endocrinally active pharmaceutical that has
been shown to affect the sexual development of male fish in
extremely low concentrations in the laboratory [51–53].
Comprehensive field surveys have also shown that intersex
fish are widespread in British rivers [54, 55]. From an
environmental risk assessment perspective, EE2 is without
doubt the most extensively studied human pharmaceutical
on the market. Nevertheless, it is very difficult to attribute
the appearance of feminized male fish in the environment to
the presence of EE2 alone since the observed effects can
result from the exposure of fish to many other stressors in
the environment that are also known to have endocrine-
disrupting effects. These include other estrogen-like and
anti-androgen-like chemicals such as the nonylphenol and
octylphenol ethoxylate surfactants and their degradation
products [56], bisphenol A [57], phthalates [56, 58], phy-
toestrogens such as genistein and equol [59] and endoge-
nous estrogen excreted from women [60, 61]. Population
level impacts have been reported in the experimental lake
studies by Kidd et al. [62] as a result of EE2 exposure albeit
at levels significantly above those found in rivers. This
illustrates the complexity associated with linking cause and
effect where several natural and synthetic chemicals are
implicated, and the body of scientific data is continuing to
grow and the full picture may not yet be clear.
3 EPV in Practice
It is clear that there are several differences between PV and
EPV and several challenges that need to be overcome if
EPV is to be effective in practice, particularly with respect
to relating cause and effect. Nevertheless, whilst EPV is
very much a developing concept, we have identified some
things that can be done to ensure that risk assessments and
scientific understanding of pharmaceuticals in the envi-
ronment remain as up to date as possible.
3.1 Environmental Risk Management Plans (ERMPs)
In AstraZeneca we have developed the concept of ERMPs
to provide a framework for capturing any environmental
risks for AstraZeneca products from early development to
launch and subsequently throughout the product life post-
launch (Fig. 1). ERMPs include information such as
physico-chemistry, pharmacokinetics, human metabolism,
preclinical toxicology and environmental data (when
available) of the Active Pharmaceutical Ingredient (API).
The ERMP enables all available environmental data to be
taken into account at key decision points during drug
development, and provides early warning of drugs that
could pose a potential risk to the environment. In addition,
it provides a framework for monitoring environmental risks
after a new product is launched, taking into account any
new information that may be available. This is analogous
to the Risk Management Plan (RMP), which includes a
number of measures to be taken for characterizing the
safety profile, mitigating and minimizing the risk to the
patient of a particular pharmaceutical. Any identified risks
can then be managed, with appropriate engagement of
regulatory authorities and interested stakeholders. If risks
are identified, appropriate follow-up measures might
include additional laboratory studies or ultimately moni-
toring for ecological effects in the environment. However,
there are very few precedents to date showing which risk
management measures could be considered beyond risk
refinement. On the one hand this is reassuring in that very
few significant risks have been identified, but it does leave
open the question of how risk mitigation would be man-
aged in practice. The only known example of a mitigation
measure beyond risk refinement is for an EE2 patch for
which special package inserts were required with instruc-
tions for proper disposal [63].
3.2 Ongoing Research to Improve Scientific
Understanding of Pharmaceuticals
in the Environment and Environmental Risk
Assessment
ERAs are by definition predictive assessments of potential
risks, normally based on experimental laboratory studies. As
scientific understanding increases, ERA practice and asso-
ciated regulatory guidance can be developed accordingly. In
many ways, the development of the current EU ERA
guideline [29] demonstrated some of the principles of EPV in
that it applied the scientific knowledge and understanding
available at the time. Consequently, the current ERA
guideline reflects that patient use and excretion result in a
widespread continuous emission of low levels of pharma-
ceuticals to the environment, and as such longer term chronic
studies with sublethal endpoints were required to indicate the
potential for population level effects. It was also recognized
that specific classes of drugs, or particular modes of action
(e.g. compounds that are designed to interact with endocrine
systems), may require additional evaluation.
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One area of current interest is whether it may be pos-
sible to predict potential effects on environmental species
from knowledge of the preclinical and clinical data for a
compound, since many of the biological receptors and
metabolic pathways present in humans are also present in
environmental species [43]. Winter et al. [64] have
reviewed some of the concepts and challenges faced in
using preclinical data, and knowledge of mode of action,
from drug discovery and development to aid in the design
of more ‘intelligent’ ERA. Such knowledge can help
identify potentially sensitive species or sensitive life-stages
that should be considered when designing appropriate
testing strategies [43]. Similarly, the physicochemical
properties, metabolism, stability and adsorption data for a
compound can help to identify relevant environmental
compartments where it may be expected to be present,
which in turn can help to focus further testing. There would
seem little point in conducting tests on species that are
unlikely to be exposed, for example.
There are many examples of individual and collaborative
research between industry, academia and government act-
ing in a proactive manner to improve the scientific under-
standing of PIE and ERA, to ensure that ERA guidance is
offering adequate levels of environmental protection. The
European Commission (EC) has funded a number of spe-
cific projects in the area. These include KNAPPE (Knowl-
edge and Need Assessment on Pharmaceutical Products in
Environmental Waters) [65], ERAPharm [66], Pharmas
[67] and Cytothreat [68]. These projects have assessed and
are currently assessing the environmental risks associated
with b-blockers, selective serotonin reuptake inhibitors,
antibiotics and cytotoxic drugs. In addition, the EC [69]
(DG SANCO, DG Environment and the Executive Agency
for Health and Consumers; EAHC) is currently reviewing
data on PIE and the potential impact on the environment
and public health, including a review of the current legis-
lation for human and veterinary drugs. Similarly there have
been some important national initiatives around the world
that have helped to inform the PIE debate, for example the
recent work undertaken by the United Kingdom Water
Industry Research (UKWIR) [70], which investigated in
detail the occurrence and removal of several micropollu-
tants, including some pharmaceuticals, in UK wastewaters.
Another example is the academia-based PIE project Mis-
traPharma [71], which aims to identify human pharma-
ceuticals that are likely to be of concern to aquatic
ecosystems, and to address the risk for promotion of anti-
biotic resistance in the environment.
Target
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Fig. 1 AstraZeneca’s Environmental Risk Management Plan
(ERMP) concept: the ERMP is initiated during drug development
to provide an early indication of any potential risks and to design an
appropriate environmental testing programme for the Active
Pharmaceutical Ingredient (API) in support of the Environmental
Risk Assessment (ERA). After launch, the ERMP is updated as
necessary if any new or emerging risks are identified as part of
AstraZeneca’s internal Ecopharmacovigilance (EPV) process
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In addition, partial and full fish life-cycle studies have
been conducted to address concerns that the acute to
chronic ratios used in risk assessment were not protective
enough for all modes of actions. These include studies on
EE2 [51], tamoxifen [72], propranolol [73], atenolol [74,
75], anastrozole and bicalutamide [76], and levonorgestrel
and drospirenone [77].
Studies have also been conducted that demonstrate that
the antiviral drug oseltamivir (Tamiflu) is unlikely to have
an impact on the environment as a result of widespread
consumption due to the global bird flu pandemic [78], and
seasonal influenza and pandemic-use conditions [79].
Antibiotics represent a class of drugs that are receiving
particular attention as the increasing prevalence of anti-
microbial resistance (AMR) in clinically important patho-
gens is undermining their efficacy. WHO has identified
options for action to combat the evolving threat of anti-
microbial resistance [80]. Many of the control measures
identified are focused on reducing the use of antibiotics and
increasing surveillance to track antimicrobial use and
resistance; they do not appear to look at natural reservoirs
of resistance and the impact that other chemical co-selec-
tors may have on the increased burden and transmission of
AMR. At a recent AMR workshop hosted by the Canadian
Society of Microbiology it was agreed that an increasing
body of data exists that demonstrates that the genes
encoding for resistance in clinically relevant bacteria
appear to be recruited from environmental bacteria [81–
83]. Therefore more research is required to determine
whether environmental input of human and veterinary
antibiotics, antibiotic-resistant bacteria, biocides and met-
als (e.g. copper and zinc) from various activities promotes
an increase in the abundance of antibiotic-resistant bacteria
in clinically important pathogens.
Finally, the Society of Environmental Toxicology and
Chemistry (SETAC) has recently published the outcomes
of a collaborative workshop that identified the top 20
questions related to PIE [84]. The workshop was attended
by experts from academia, governments and industry from
around the world and provides an important summary of
current knowledge gaps and future research needs. Some of
the key recommendations for further research work were to
(i) conduct a comparative assessment between pharma-
ceuticals and other environmental stressors to determine
their relative impact on human and environmental health,
(ii) determine whether environmental exposure to antibi-
otic residues results in adverse human health outcomes
through the spread of antimicrobial resistance to clinically
important pathogens, and (iii) link mode of action-based
biomarker responses to ecologically important adverse
outcome pathways.
These examples highlight just some of the proactive and
collaborative approaches to product stewardship and
research on PIE. They also demonstrate that all interested
stakeholders from regulatory agencies, academia, non-
governmental organizations and industry are actively
engaged in the debate. Such initiatives demonstrate many
of the principles of EPV and are essential for improving
our understanding of the science of PIE. The outcomes
ultimately may lead to improvements in ERA practices and
can help to inform the revisions of future ERA regulation.
3.3 Literature Monitoring and ERA/ERMP Refinement
Within AstraZeneca, alongside our research activities we
routinely monitor the literature for any newly published
information relating to our products. Depending on the
significance of any findings, such data may then be used to
refine the ERA assumptions, and update the ERMPs as
appropriate. In practice this generally requires identifying
and assessing any relevant published ecotoxicological
information that could impact the PNEC and any infor-
mation on fate and exposure that might impact on the PEC.
This includes any data on the occurrence of the APIs in the
environment and deciding how such findings should be
interpreted, for example whether measured concentrations
relate to manufacturing or hospital discharges or whether
they are indicative of more widespread concentrations
associated with normal patient use and excretion into
domestic wastewater. To be used in ERA directly, any
published information, including non-standard data, needs
to be sufficiently robust, for example following the criteria
laid out by Klimisch et al. [85], Kt‹ ster et al. [86] and
A˚gerstrand et al. [87]. If relevant information is identified,
and if there is an established link between the endpoint and
an adverse population effect [88], this can then be used to
refine the ERA assumptions as appropriate, and options for
further risk refinement, risk management or further
research can then be considered in the ERMP. It is also
important to recognise that publications of biomarker
endpoints can also be useful to direct future research
activities [89], but it is equally important that such studies
include sufficient supporting information so that the data
may be interpreted appropriately.
3.4 Refining ERAs when the Ratio of the Predicted
Environmental Concentration to the Predicted
No-Effect Concentration is [1
If the PEC:PNEC is [1, further refinement of the risk
assessment is generally appropriate. This might require
additional targeted testing to refine the PEC or the PNEC.
Another option might be to undertake targeted monitoring
of concentrations in the environment in order to confirm
whether the PEC calculations are reasonable. The choice of
follow-up measure adopted is likely to be decided on a
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case-by-case basis, reflecting the nature of the risks iden-
tified and the data available for the specific compound in
question.
Propranolol is a good example of an API for which a
significant amount of follow-up work was triggered based
on initial ERA findings. The original work from Huggett
et al. [90, 91] suggested that the concentrations in the
environment may lead to harmful effects in fish. This then
led to several research projects, including the major EC-
funded project ERAPharm, which focused not only on
propranolol, but on other b-blockers, such as atenolol, in
order to improve understanding of the risks associated with
this group of compounds. The work of ERAPharm and
other research have helped to provide new data to refine the
original risk assessment [75]. These focused studies
showed that propranolol biodegraded in the environment
(indeed it was readily mineralized in some tests). It is also
readily photodegraded [92, 93], and unlikely to bioaccu-
mulate [94, 95]. There is also now much more ecotoxicity
data available, including chronic fish studies [95], such that
the weight of evidence suggests that propranolol is not as
toxic to fish as previously thought. Perhaps most impor-
tantly, it is also now clear that not all b-blockers have the
same ecotoxicity profile, since the lowest ‘No Observed
Effect Concentration’ (NOEC) for atenolol [75], for
example, is over two orders of magnitude higher (less
toxic) than the lowest NOEC for propranolol [26]. Overall
these data provide reassuring answers to the questions that
the original assessments posed. Figure 2 shows that, from
all the available surface water-monitoring data of pro-
pranolol in the environment, in most cases the measured
data are lower than the PNEC, with the exception of about
10 % of cases. These data represent a broad range of
sampling regimens (e.g., spot and composite samples) and
different types of measurements (e.g., peak vs. mean con-
centrations), so care is needed when interpreting the
results. However, on face value the data provide an indi-
cation of where the potential risk may be highest and where
further investigation might be needed. There are many
potential reasons why the risks may be higher in some
areas, for example if there is inadequate wastewater treat-
ment, and/or particularly high population density or low
dilution capacity in the receiving environment. Whatever
the reason, such an analysis, when cross-referenced to
specific locations, enables researchers to target further
investigations in those local geographical areas where the
potential for risk is higher, thereby making best use of
available resources.
For drugs that are relatively data rich, species sensitivity
distributions have been generated with all the environ-
mental effects data to provide more confidence in the
effects and risk assessment. Two examples of such an
approach are the work of Caldwell et al. [96] for EE2, and
the deterministic and probabilistic risk assessment of
naproxen by Straub and Stewart [97]. Further refinement in
the PEC values for EE2 have been made based on the
results from the PhATE (Pharmaceutical Assessment and
Transport Evaluation) and GREAT-ER (Geography Ref-
erenced Regional Exposure Assessment Tool for European
Rivers) models to identify the 90th-percentile low-flow




























Fig. 2 Published Measured
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3.5 Keeping a Global EPV Perspective
Current ERA practices largely reflect EU and US phar-
maceutical use patterns and the potential risks associated
with drugs in those regions. Just as PV addresses regional
differences, so too should ERAs be designed to ensure
protection in any region where the drug will be used.
Whilst many areas of the European Medicines Agency
(EMA) ERA guideline have global relevance, there may be
some inherent assumptions that are not applicable in other
regions. For example, the EMA guideline does not consider
irrigation as a potential route to the terrestrial environment,
whilst this is normal practice in some parts of the world,
particularly in water-stressed areas. Similarly, disease
prevalence, cultural practices and climate are different in
different parts of the world, so the risk profile associated
with a pharmaceutical agent may also be different. The
challenge is to identify what region-specific exposure
scenarios may need to be considered, recognizing that this
may not always be straightforward, especially when con-
sidering uses such as for example the veterinary use of
diclofenac in cattle. A major reason for the unanticipated
impact of diclofenac on vulture populations was the sen-
sitivity of certain raptors to diclofenac and a failure of the
risk assessment to recognise this exposure route. Secondary
poisoning of raptors has previously been recognised and
mitigated against. For example, bald and golden eagles,
other wildlife and domestic dogs have been intoxicated or
killed after ingestion of pentobarbital residues present in
tissues of euthanized carcasses that have been disposed of
inadequately [99]. In order to control these risks, disposal
procedures were tightened (e.g., incineration of euthanized
carcasses or immediate deep burial) and penalties for the
violation of appropriate disposal were developed. Thus, it
is certainly relevant, and arguably the essence of EPV, to
ask the question whether the vulture decline could have
been detected earlier if this exposure route had been
identified before employing widespread use in cattle. As
pointed out by Winter et al. [64], if this exposure route had
been considered, then this might have triggered targeted
effects testing on carrion-feeding birds. This underlines the
importance of consideration of the patterns of compound
usage, local cultural and agricultural practices, and ecology
of the species assessed, in order to explain the patterns of
contamination observed.
3.6 Transparency with Data
One of the ways to encourage effective EPV practices is to
ensure that relevant environmental information is shared
between government, academia, industry and other inter-
ested stakeholders. For several years environmental data
have been made publically available in the Swedish
Prescribing guide [100], which includes environmental risk
information of the API, based on the PEC/PNEC ratio, as
well as information about degradation and bioaccumula-
tion, and results from environmental studies. Environ-
mental data for AstraZeneca products are now also
available on their corporate responsibility webpages [101].
The information available on AstraZeneca.com is slightly
different to that on Fass.se in that it considers an EU-wide
risk assessment, rather than a Swedish-based one; however,
both systems are based on the total API volume used in all
products, from all companies, containing the same active
ingredient. It is hoped that this transparency will contribute
to the scientific knowledge about environmental properties
of API. It is notable that the EMA has recently made sig-
nificant changes to its policy on data transparency [102]. It
is not yet clear how this will work in practice but it is likely
that much of the ERA information that is provided as part
of the regulatory submission will be more publically
accessible in future.
3.7 Identifying Adverse Environmental Impacts
One of the key challenges for EPV is that any observations
of ecological trends or adverse effect in the environment
will almost certainly not (at least initially) be identified as
being associated with any one particular cause. It took
several years to identify the cause of the vulture decline
due to diclofenac poisoning. Similarly, research into the
causes and consequences of intersex in fish is now well into
its second decade, with no single cause having been
identified. Whether there is a long-term population-level
impact is also still uncertain and is dependent on the
severity of feminized males [103, 104]. Another key
challenge for EPV is that in the environment there are
many different species that may be potentially exposed;
however, it is simply not possible to monitor all of them. In
contrast, with PV, it is usually possible to monitor all
patients who are taking a particular drug.
Biological monitoring studies of species, species
assemblages and ecosystems are being undertaken all the
time by a range of researchers in many parts of the world.
These may identify adverse or unexpected effects of
unknown cause and such observations may (or may not)
subsequently be included in reports or scientific publica-
tions. However, even if the observations are reported they
are, in effect, randomly distributed throughout the literature
and there is currently no worldwide process, other than
serendipity, whereby connections might be made and
restorative action initiated.
In the EU, this type of monitoring activity already forms
the central core of the Water Framework Directive (WFD),
and requires that every watercourse within the EU27 has to
be monitored periodically to determine its ecological
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status. Those that do not comply with the conditions for
‘‘good ecological’’ status must be subjected to further
investigation to determine the reason for their non-com-
pliance. Once the reasons have been established, plans then
need to be drawn up and implemented to remedy the
deficiency.
In terms of pharmaceuticals, it would be expected that
any adverse impact in the aquatic environment would occur
where the environmental residue concentration was high-
est, for example in the vicinity of outfalls from large
wastewater treatment plants. Consequently, within the EU
any such adverse impacts could emerge from the ecological
monitoring being undertaken for the WFD, although attri-
bution of cause and effect is still likely to be extremely
difficult unless there is a very substance-specific effect. In
addition, potential adverse environmental impacts in spe-
cies living in the terrestrial or atmospheric environment
would be unlikely to be identified from the activities within
the WFD. It should also be noted that ecological moni-
toring is undertaken at a local level with no formal
mechanism for sharing data on adverse impacts either
between or even within member states.
4 Discussion
The above sections highlight some of the challenges
associated with EPV and some of the practical measures
that can be undertaken to ensure that the ERA under-
standing of a drug remains up to date and globally relevant
throughout the life of a new drug.
Most of the pro-active measures proposed here often form
part of the research activities that are already undertaken by
pharmaceutical companies, academics and governments,
sometimes collaboratively, and are not part of any regulatory
requirement. However, it is also clear in the EU Medicines
Directive that if a risk is identified in the ERA follow-up
work is required to refine the ERA or identify appropriate
‘‘specific arrangements to limit it’’. Thus, in principle the
mechanism exists in the EU to manage risks effectively for
new medicinal products and line extensions, providing those
risks are identified before approval.
One additional challenge for EPV is that many older
established drugs pre-date current regulatory requirements
for environmental risk assessment. Of approximately 4,000
APIs on the market today only about 10 % have sufficient
data to enable a PEC:PNEC value to be calculated [84]. For
these drugs there is typically considerably more informa-
tion on their occurrence in the environment than there is on
their effects. Thus, the significance of trace levels of these
drugs in the environment is often poorly understood. The
challenge is to identify which of these APIs should be
prioritized for further evaluation.
In an attempt to address this challenge, Roos et al.
[105] have used nine prioritization schemes to prioritize
and rank 582 human drugs based on environmental hazard
and risk. Due to the availability of data, not all these drugs
could be assessed. The authors favoured risk-based
approaches over hazard-based systems, as environmental
risk reflects both exposure and impact, and recommended
that hazard-based approaches should only be applied for
human drugs where insufficient exposure data exist. Using
the traditional PEC:PNEC prioritization approach on 196
human drugs, for which robust data were available, they
identified seven with a PEC:PNEC [1, indicating that,
where sufficient data exist for analysis, the majority
of pharmaceuticals pose no significant risk to the
environment.
5 Summary and Conclusions
In this article we have accepted the definition of EPV based
upon the WHO definition of PV:
Ecopharmacovigilance is the science and activities
associated with the detection, evaluation, understanding
and prevention of adverse effects of pharmaceuticals in the
environment.
We have presented some ideas on what EPV might
mean in practice, together with some challenges and
opportunities for implementing EPV procedures. We sug-
gest that the main focus of EPV should be after launch of a
drug, which will help to identify any possible risks
throughout the life of the product. It should be emphasized
that EPV is a developing science, still very much in its
infancy, and there is therefore room for further debate and
research before any formalized approach to EPV is
established.
We have identified that there are many similarities
between EPV and PV, but also some important differences
that have implications for any practical implementation of
EPV. In particular, to determine a causal relationship
between a drug and an ADR is not straightforward in terms
of a patient, but nowhere near as difficult as attributing
adverse impacts in environmental species to a single drug.
However, we have identified some approaches that can
be taken, including;
• Tracking environmental risks after launch of the
product, via literature monitoring for emerging data,
and by use of Environmental Risk Management Plans
• Further research, testing or monitoring in the environ-
ment when a risk is identified
• Keeping a global EPV perspective
• Increasing transparency and availability of environ-
mental data for medicinal products.
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These measures will help to ensure that any issues
associated with PIE are identified in a timely way, and can
be managed appropriately. In addition, research in this area
will continue, and the SETAC 20 questions publication
[84] has provided a comprehensive summary of the current
state of science of PIE and has identified clear areas where
future research is needed.
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